{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:24:16Z","timestamp":1778502256153,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,15]]},"DOI":"10.2146\/ajhp110486","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T17:18:25Z","timestamp":1338311905000},"page":"1038-1043","source":"Crossref","is-referenced-by-count":20,"title":["Risk of hypotension with concomitant use of calcium-channel blockers and macrolide antibiotics"],"prefix":"10.1093","volume":"69","author":[{"given":"Amy","family":"Henneman","sequence":"first","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisy-Ann","family":"Thornby","sequence":"additional","affiliation":[{"name":"Lloyd L. Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"issue":"suppl 1","key":"2019041203515233400_b1-0691038","first-page":"94","article-title":"Prevalence of hypertension and controlled hypertension\u2014United States, 2005\u20132008","volume":"60","author":"Keenan","year":"2011","journal-title":"MMWR Surveill Summ"},{"key":"2019041203515233400_b2-0691038","first-page":"103","article-title":"Vital signs: prevalence, treatment, and control of hypertension\u2014United States, 1999\u20132002 and 2005\u20132008","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR"},{"key":"2019041203515233400_b3-0691038","unstructured":"IMS Health Institute for Informatics. Top therapeutic classes by prescriptions. In: The use of medicines in the United States: review of 2010. www.imshealth.com\/imshealth\/Global\/Content\/IMS%20Institute\/Documents\/IHII_UseOfMed_report%20.pdf (accessed 2012 Mar 8)."},{"key":"2019041203515233400_b4-0691038","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0011-393X(03)00023-7","article-title":"A multicenter, case-control study of the effects of antihypertensive therapy on orthostatic hypotension, postprandial hypotension, and falls in octo- and nonagenarians in residential care facilities","volume":"64","author":"Fisher","year":"2003","journal-title":"Curr Ther Res"},{"key":"2019041203515233400_b5-0691038","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/pgmj.70.830.878","article-title":"Orthostatic hypotension and antihypertensive therapy in the elderly","volume":"70","author":"Fotherby","year":"1994","journal-title":"Postgrad Med J"},{"key":"2019041203515233400_b6-0691038","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1001\/jama.1987.03400110093033","article-title":"Low prevalence of postural hypotension among community-dwelling elderly","volume":"258","author":"Mader","year":"1987","journal-title":"JAMA"},{"key":"2019041203515233400_b7-0691038","unstructured":"Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. www.fda.gov\/drugs\/developmentapprovalprocess\/developmentresources\/druginteractionslabeling\/ucm093664.htm (accessed 2012 Mar 7)."},{"key":"2019041203515233400_b8-0691038","unstructured":"Lexi-Drugs Online. Lexi-CompOnline website. http:\/\/online.lexi.com\/crlsql\/servlet\/crlonline (accessed 2011 Nov 9)."},{"key":"2019041203515233400_b9-0691038","volume-title":"DRUGDEX System [Internet database]"},{"key":"2019041203515233400_b10-0691038","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1503\/cmaj.100702","article-title":"The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers","volume":"183","author":"Wright","year":"2011","journal-title":"CMAJ"},{"key":"2019041203515233400_b11-0691038","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1093\/ajhp\/55.22.2417","article-title":"Severe hypotension and bradycardia associated with verapamil and clarithromycin","volume":"55","author":"Kaeser","year":"1998","journal-title":"Am J Health-Syst Pharm"},{"key":"2019041203515233400_b12-0691038","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1345\/aph.10396","article-title":"Compound cardiac toxicity of oral erythromycin and verapamil","volume":"35","author":"Goldschmidt","year":"2001","journal-title":"Ann Pharmacother"},{"key":"2019041203515233400_b13-0691038","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1345\/aph.17240","article-title":"Potential macrolide interaction with verapamil","volume":"32","author":"Steenbergen","year":"1998","journal-title":"Ann Pharmacother"},{"key":"2019041203515233400_b14-0691038","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1345\/aph.1E432","article-title":"Clarithro-mycin-nifedipine interaction as possible cause of vasodilatory shock","volume":"39","author":"Ger\u00f3nimo-Pardo","year":"2005","journal-title":"Ann Pharmacother"},{"key":"2019041203515233400_b15-0691038","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/106002809102500918","article-title":"Erythromycin-felodipine interaction","volume":"25","author":"Liedholm","year":"1991","journal-title":"DICP"},{"key":"2019041203515233400_b16-0691038","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0009-9236(96)90163-0","article-title":"Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice","volume":"60","author":"Bailey","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"2019041203515233400_b17-0691038","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa040582","article-title":"Oral erythromycin and the risk of sudden death from cardiac causes","volume":"351","author":"Ray","year":"2004","journal-title":"N Engl J Med"},{"key":"2019041203515233400_b18-0691038","volume-title":"Biaxin (clarithromycin) package insert","year":"2011"},{"key":"2019041203515233400_b19-0691038","volume-title":"Erythromycin delayed-release capsules package insert","year":"2009"},{"key":"2019041203515233400_b20-0691038","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/12\/1038\/28361317\/ajhp1038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T23:46:05Z","timestamp":1555112765000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/12\/1038\/5112759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,15]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,6,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110486","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,15]]},"published":{"date-parts":[[2012,6,15]]}}}